{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:56:39Z","timestamp":1779378999684,"version":"3.53.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejca.2021.07.021","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T12:09:14Z","timestamp":1630152554000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study"],"prefix":"10.1016","volume":"164","author":[{"given":"Ningjing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xielan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiman","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.07.021_bib1","series-title":"NCCN clinical practice guidelines in Oncology (NCCN guidelines). Hodgkin lymphoma","year":"2020"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.021_bib2","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.021_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"issue":"9844","key":"10.1016\/j.ejca.2021.07.021_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.021_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12185-018-2404-8","article-title":"Current status and progress of lymphoma management in China","volume":"107","author":"Shi","year":"2018","journal-title":"Int J Hematol"},{"issue":"32","key":"10.1016\/j.ejca.2021.07.021_bib6","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2021.07.021_bib7","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2021.07.021_bib8","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.021_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.021_bib10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2021.07.021_bib11","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage hodgkin's lymphoma: national cancer Institute of Canada clinical trials group and the eastern cooperative Oncology group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2021.07.021_bib12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.021_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.021_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.ejca.2021.07.021_bib15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2021.07.021_bib16","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2021.07.021_bib17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ejca.2021.07.021_bib18","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1182\/blood-2018-99-115626","article-title":"Real-World outcomes of high-risk multiple myeloma: retrospective analysis of Cams&pumc","volume":"132","author":"Sui","year":"2018","journal-title":"Blood"},{"issue":"10, Supplement","key":"10.1016\/j.ejca.2021.07.021_bib19","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1016\/j.clml.2019.09.382","article-title":"Treatment of newly diagnosed multiple myeloma: a real-world study in A western single center of China","volume":"19","author":"Liao","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.021_bib20","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.ejca.2021.07.021_bib21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.021_bib22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2021.07.021_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2019.37.4_suppl.125","article-title":"Gls-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: result of a phase Ib clinical trial","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Supplement 10","key":"10.1016\/j.ejca.2021.07.021_bib24","doi-asserted-by":"crossref","first-page":"X22","DOI":"10.1093\/annonc\/mdy486.017","article-title":"A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: result of a phase Ia clinical trial","volume":"29","author":"Shen","year":"2018","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.07.021_bib25","article-title":"GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin's lymphoma: preliminary result of a phase II clinical trial","volume":"37","author":"Song","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.021_bib26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ejca.2021.07.021_bib27","first-page":"63","article-title":"The evolving role of brentuximab vedotin in classical hodgkin lymphoma","volume":"9","author":"Lai","year":"2019","journal-title":"Blood Lymphat Cancer"},{"issue":"Suppl 33","key":"10.1016\/j.ejca.2021.07.021_bib28","doi-asserted-by":"crossref","first-page":"S4065","DOI":"10.21037\/jtd.2018.09.83","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer\": is there a substantial difference or not?","volume":"10","author":"Spagnuolo","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2021.07.021_bib29","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3389\/fonc.2019.00972","article-title":"Comparative safety of PD-1\/PD-L1 inhibitors for cancer patients: systematic review and network meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.021_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.021_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/abt\/tby005","article-title":"Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer","volume":"1","author":"Zhang","year":"2018","journal-title":"Antibody Ther"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:51Z","timestamp":1760733351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"alternative-id":["S0959804921004792"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}